Positive clinical trial results often lead to increased investor confidence, as they indicate potential for future revenue through new product approvals. The announcement of the early unblinding of the trial due to significant efficacy improvement is particularly promising, suggesting a high likelihood of FDA approval for Cabozantinib. This could lead to increased demand for Exelixis's stock, driving up its price in the short term.